CN107586796B - Synthesis method of (R) -2- (1-aminoethyl) -4-fluorophenol - Google Patents
Synthesis method of (R) -2- (1-aminoethyl) -4-fluorophenol Download PDFInfo
- Publication number
- CN107586796B CN107586796B CN201710593645.4A CN201710593645A CN107586796B CN 107586796 B CN107586796 B CN 107586796B CN 201710593645 A CN201710593645 A CN 201710593645A CN 107586796 B CN107586796 B CN 107586796B
- Authority
- CN
- China
- Prior art keywords
- reaction
- aminoethyl
- transaminase
- solution
- synthesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- SSNRPTHWRFURQQ-RXMQYKEDSA-N 2-[(1r)-1-aminoethyl]-4-fluorophenol Chemical compound C[C@@H](N)C1=CC(F)=CC=C1O SSNRPTHWRFURQQ-RXMQYKEDSA-N 0.000 title claims description 16
- 238000001308 synthesis method Methods 0.000 title abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims abstract description 33
- 102000003929 Transaminases Human genes 0.000 claims abstract description 26
- 108090000340 Transaminases Proteins 0.000 claims abstract description 26
- 238000003756 stirring Methods 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000005515 coenzyme Substances 0.000 claims abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 14
- 239000007853 buffer solution Substances 0.000 claims abstract description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 13
- 239000006184 cosolvent Substances 0.000 claims abstract description 9
- 239000000758 substrate Substances 0.000 claims abstract description 9
- 238000000605 extraction Methods 0.000 claims abstract description 8
- 238000010438 heat treatment Methods 0.000 claims abstract description 8
- 239000002904 solvent Substances 0.000 claims abstract description 8
- 238000000746 purification Methods 0.000 claims abstract description 6
- KOFFXZYMDLWRHX-UHFFFAOYSA-N 1-(5-fluoro-2-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC(F)=CC=C1O KOFFXZYMDLWRHX-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000047 product Substances 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000000967 suction filtration Methods 0.000 claims description 16
- 239000012071 phase Substances 0.000 claims description 14
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 238000003786 synthesis reaction Methods 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 9
- 229940011051 isopropyl acetate Drugs 0.000 claims description 9
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 9
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims description 7
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims description 7
- 229960001327 pyridoxal phosphate Drugs 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 239000012065 filter cake Substances 0.000 claims description 5
- 239000012074 organic phase Substances 0.000 claims description 5
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical group CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims description 4
- BHRZNVHARXXAHW-UHFFFAOYSA-N sec-butylamine Chemical compound CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 claims description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 claims description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 239000012295 chemical reaction liquid Substances 0.000 claims description 3
- 229950010030 dl-alanine Drugs 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims 1
- 235000019797 dipotassium phosphate Nutrition 0.000 claims 1
- 238000010189 synthetic method Methods 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 230000003287 optical effect Effects 0.000 abstract description 4
- 238000002425 crystallisation Methods 0.000 abstract description 2
- 230000008025 crystallization Effects 0.000 abstract description 2
- JLTCGWBRNSZJIX-RXMQYKEDSA-N 2-[(1R)-1-aminoethyl]-4-fluoroaniline Chemical compound N[C@H](C)C1=C(N)C=CC(=C1)F JLTCGWBRNSZJIX-RXMQYKEDSA-N 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006555 catalytic reaction Methods 0.000 description 5
- 230000002194 synthesizing effect Effects 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000012752 auxiliary agent Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 1
- FDUBQNUDZOGOFE-UHFFFAOYSA-N 5-fluoro-2-hydroxybenzaldehyde Chemical compound OC1=CC=C(F)C=C1C=O FDUBQNUDZOGOFE-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- JYPIENNPOPULKF-UHFFFAOYSA-N s-butylthiohydroxylamine Chemical group CCCCSN JYPIENNPOPULKF-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention provides a synthesis method of (R) -2- (1-aminoethyl) -4-fluoroaniline, which comprises the following steps of uniformly stirring an amino donor, coenzyme, a cosolvent, transaminase dry powder and a buffer solution, adding a substrate 5-fluoro-2-hydroxyacetophenone, and heating to 25-35 ℃ in a vacuum system of-0.03 MPa to-0.06 MPa for reaction; and after the reaction is finished, carrying out post-treatment and purification to obtain a target product. The invention adopts biocatalyst-omega-transaminase, and greatly improves the chiral purity of the reaction due to the high-efficiency selectivity of the enzyme. The method can obtain qualified products after simple acid-base extraction, concentration and crystallization by adding a poor solvent, and the optical purity and yield of the product prepared by the method are improved to a great extent.
Description
Technical Field
The invention relates to a method for synthesizing (R) -2- (1-aminoethyl) -4-fluorophenol by transaminase catalysis, belonging to the technical field of enzyme catalysis and biological pharmacy.
Background
Chiral amines are structural units of many important bioactive molecules, are important intermediates for synthesizing natural products and chiral drugs, and can also become important chiral auxiliary agents and chiral resolution reagents. The preparation method of the chiral amine has important economic significance.
(R) -2- (1-aminoethyl) -4-fluorophenol is an important intermediate for anticancer drugs, and a world patent WO2017007759 published by TP Therapeutics in the U.S. discloses a broad-spectrum protein kinase regulator which can effectively aim at multiple acquired mutations, thereby providing a brand-new method for treating cancers. This type of chemical entity drug contains (R) -2- (1-aminoethyl) -4-fluorophenol intermediate, which patent discloses the synthesis of this structure, as shown in the following reaction scheme:
the method comprisesR-tert-butyl sulfinamide is used as a chiral auxiliary agent, and then nucleophilic addition reaction is carried out on methyl magnesium bromide and an imine intermediate at low temperature (-65 ℃), so as to obtain a chiral center; then removing the protecting group tert-butylsulfinyl to obtain the target product. The method uses 2-hydroxy-5-fluorobenzaldehyde as initial raw material and chiral auxiliary agentRThe tertiary butyl sulfenamide is expensive and has higher cost; how selective the second step is induced by chirality is not mentioned; the second addition reaction is carried out at low temperature, making scale-up of the scheme difficult. Therefore, it is necessary to develop an industrial scheme which is cheap, has high conversion rate and is easy to operate.
The chemical method for synthesizing chiral amine mainly comprises asymmetric catalysis, chiral auxiliary agent induction, salt formation and resolution with chiral acid and the like; however, these methods have disadvantages of long steps, high cost, low yield, and difficult operation of reaction conditions.
The transaminase can transfer ammonia of an amino donor to prochiral ketone in a catalytic manner, so that chiral amine is directly synthesized in one step, and a simple and efficient method for synthesizing the chiral amine is provided.
The enzyme catalysis kinetic resolution develops rapidly in recent years, and has attracted people's interest due to the advantages of high efficiency, high selectivity, mild reaction conditions, environmental friendliness and the like. The asymmetric synthesis of chiral amines by transaminases has been exemplified by the successful application and industrial production since the 80's of the 20 th century.
Disclosure of Invention
In view of the above-mentioned drawbacks of the prior art, the present invention provides a process for the transaminase-catalyzed synthesis of (R) -2- (1-aminoethyl) -4-fluorophenol.
The purpose of the invention is realized by the following technical scheme:
a method for synthesizing (R) -2- (1-aminoethyl) -4-fluorophenol comprises the following steps of uniformly stirring an amino donor, coenzyme, a cosolvent, transaminase dry powder and a buffer solution, adding a substrate 5-fluoro-2-hydroxyacetophenone, and heating to 25-35 ℃ under a vacuum system of-0.03 MPa to-0.06 MPa to react; and after the reaction is finished, carrying out post-treatment and purification to obtain a target product.
Preferably, the method comprises the following steps:
s1, preparing a solution of a raw material, namely preparing coenzyme into a coenzyme aqueous solution, and preparing an amino donor into an amino donor aqueous solution;
s2, adding the prepared solution in the S1 into a reaction bottle added with a buffer solution, and stirring and mixing, wherein the pH value of the buffer solution is 7-9;
s3, adding transaminase dry powder into the mixed solution of S2, uniformly stirring, adding cosolvent in which a substrate is dissolved, wherein the weight ratio of the transaminase dry powder to the substrate is 0.5-1%, keeping the vacuum degree of the system at-0.03 MPa to-0.06 MPa, heating to 25-35 ℃, and carrying out stirring reaction;
s4, stopping stirring when the content of the raw materials in the reaction liquid phase in the S3 is less than 1.0%, and finishing the reaction;
and S5, carrying out suction filtration and purification post-treatment on the solution after the reaction to obtain the target product.
Preferably, the S5 specifically includes the following steps:
s51, carrying out suction filtration on the solution after the reaction is finished, rinsing a filter cake, and transferring the filtrate;
s52, adjusting the pH of the transferred filtrate to 3-4, and adding an extraction solvent to extract a water phase;
s53, cooling the extracted water phase to 10-20 ℃, adjusting the pH to 7-8, and re-extracting the water phase;
s54, washing the organic phase extracted by the S53 with water, washing with saline water, drying and filtering in sequence;
s55, concentrating the filtrate obtained after the suction filtration of S54;
and S56, performing suction filtration again, and drying to obtain the final target product.
Preferably, the amino donor is isopropylamine, sec-butylamine or DL-alanine.
Preferably, the coenzyme in S1 is pyridoxal phosphate.
Preferably, the concentration range of the coenzyme is 10.0 mmoL/L-20.0 mmoL/L.
Preferably, the cosolvent is dimethyl sulfoxide, N-dimethylformamide, methanol, ethanol, acetonitrile, or isopropanol.
Preferably, the transaminase of the dry transaminase powder is an R-configuration selective transaminase commercialized by the german biocatalysis company, evox technologies, including the following types: cat.no. 1.2.125, cat.no. 1.2.126, cat.no. 1.2.131, cat.no. 1.2.132, cat.no. 1.2.133, cat.no. 1.2.134, cat.no. 1.2.135, cat.no. 1.2.136, and cat.no. 1.2.137, and further can preferably be cat.no. 1.2.126, cat.no. 1.2.131, or cat.no. 1.2.132.
Preferably, the buffer is an aqueous potassium phosphate solution or a tris buffer.
Preferably, the extraction solvent in S52 is ethyl acetate, isopropyl acetate, dichloromethane, toluene, or methyl t-butyl ether.
The invention has the beneficial effects that: the chiral purity of the reaction is greatly improved by adopting the biocatalyst-omega-transaminase due to the high-efficiency selectivity of the enzyme. Meanwhile, because the enzyme is a biological macromolecule easy to degrade, the pollution caused by multi-step chemical synthesis is avoided. The reaction conversion rate is high, and the target product can be obtained by one-step reaction. The method has the advantages of mild conditions and low reaction temperature, because the product is amine with phenolic hydroxyl, the product is easy to decompose at high temperature, the degradation of the compound is avoided, the qualified product can be obtained by simple acid-base extraction, concentration and crystallization by adding a poor solvent after the post-treatment, and the optical purity and the yield of the product prepared by the method are improved to a great extent.
The following detailed description of the embodiments of the present invention is provided in connection with the accompanying drawings for the purpose of facilitating understanding and understanding of the technical solutions of the present invention.
Drawings
FIG. 1: high performance liquid chromatogram of the product of the first example.
FIG. 2: chiral liquid chromatogram of the product of this example one.
FIG. 3: nuclear magnetic hydrogen spectra of the product of the first example.
Detailed Description
The invention provides a synthesis method of (R) -2- (1-aminoethyl) -4-fluorophenol, which comprises the following steps:
s1, preparing a solution of a raw material, namely preparing coenzyme into a coenzyme aqueous solution, and preparing an amino donor into an amino donor aqueous solution; the amino donor is isopropylamine, sec-butylamine or DL-alanine. The coenzyme is pyridoxal phosphate, and the concentration range of the coenzyme is 10.0 mmoL/L-20.0 mmoL/L.
S2, adding the prepared solution in the S1 into a reaction bottle added with a buffer solution, and stirring and mixing, wherein the pH value of the buffer solution is 7-9; the buffer solution is potassium phosphate aqueous solution or tris buffer solution.
S3, adding transaminase dry powder into the mixed solution of S2, uniformly stirring, adding cosolvent in which a substrate is dissolved, wherein the weight ratio of the transaminase dry powder to the substrate is 0.5-1%, keeping the vacuum degree of the system at-0.03 MPa to-0.06 MPa, heating to 25-35 ℃, and carrying out stirring reaction; the cosolvent is dimethyl sulfoxide, N-dimethylformamide, methanol, ethanol, acetonitrile or isopropanol. The transaminase R-configuration selective transaminase of the dry transaminase powder adopts R-configuration selective transaminase commercialized by Evox technologies of Germany biological catalysis company, and comprises the following types: cat.no. 1.2.125, cat.no. 1.2.126, cat.no. 1.2.131, cat.no. 1.2.132, cat.no. 1.2.133, cat.no. 1.2.134, cat.no. 1.2.135, cat.no. 1.2.136, and cat.no. 1.2.137, and further can preferably be cat.no. 1.2.126, cat.no. 1.2.131, or cat.no. 1.2.132.
S4, stopping stirring when the content of the raw materials in the reaction liquid phase in the S3 is less than 1.0%, and finishing the reaction;
and S5, carrying out suction filtration and purification post-treatment on the solution after the reaction to obtain the target product.
S51, carrying out suction filtration on the solution after the reaction is finished, rinsing a filter cake, and transferring the filtrate;
s52, adjusting the pH of the transferred filtrate to 3-4, and adding an extraction solvent to extract a water phase; the extraction solvent is ethyl acetate, isopropyl acetate, dichloromethane, toluene or methyl tert-butyl ether.
S53, cooling the extracted water phase to 10-20 ℃, adjusting the pH to 7-8, and re-extracting the water phase;
s54, washing the organic phase extracted by the S53 with water, washing with saline water, drying and filtering in sequence;
s55, concentrating the filtrate obtained after the suction filtration of S54;
and S56, performing suction filtration again, and drying to obtain the final target product.
Example one
150mL of a dipotassium hydrogen phosphate buffer solution (pH 8) was added to a 2L reaction flask, 150mL of a 10 mmol/L aqueous solution of pyridoxal phosphate coenzyme (PLP) prepared in advance was added, 1.29L of a 1M/L aqueous solution of isopropylamine (the pH of the aqueous solution was adjusted to 8 with 10% phosphoric acid) prepared in advance was added, and stirring was slowly started. Then 15mg of dry transaminase powder of Cat.No. 1.2.126 was added, and after stirring for 5 minutes, a dimethyl sulfoxide solution of 2-hydroxy-5-fluoroacetophenone (10 g of the starting ketone was dissolved in 75mL of dimethyl sulfoxide) was added. The vacuum is opened to the system of-0.03 MPa. The heating was turned on to 35 ℃. The liquid phase after 18h of reaction showed <1.0% starting material remaining. Stirring was stopped, suction filtered and the filter cake rinsed with 50mL of isopropyl acetate. The filtrate was transferred to a 5L reaction flask and 1M/L dilute hydrochloric acid was added with stirring to adjust the pH of the system to 3-4. The aqueous phase was then extracted by adding 200mL of isopropyl acetate. After liquid separation, cooling the water phase to 10-20 ℃, and then adding 20% NaOH solution to adjust the pH of the system to 7-8. The aqueous phase was then extracted with 300mL of isopropyl acetate. And sequentially washing the extracted organic phase with water, washing with brine, drying with anhydrous sodium sulfate and performing suction filtration. Concentrating the filtrate to about 50mL, and adding 50mL of n-heptane; the system is concentrated again to the volume of about 30mL, and a large amount of product is separated out; suction filtration and drying to obtain 7.85g of off-white solid with optical purity of 99.5% and yield of 78%.
The product in the example is subjected to performance analysis, specifically shown in fig. 1-3, wherein the retention time of the S configuration in fig. 2 is 33.2min, and the retention time of the R configuration is 35.6 min. The retention time refers to the position of the peak of the different products when the content of the liquid phase is measured. The R configuration selective transaminase is produced predominantly with the product of the R configuration but with a small amount of the product of the S configuration, the ratio of which indicates the efficiency of the transaminase.
Example two
150mL of Tris-HCl buffer solution (pH 8), 150mL of 10 mmol/L aqueous solution of coenzyme pyridoxal phosphate (PLP) prepared in advance, and 1.29L of 1.0M/L aqueous solution of sec-butylamine (the pH of the aqueous solution is adjusted to 8 by 10% phosphoric acid) prepared in advance are sequentially added into a 2L reaction flask, and stirring is slowly started; then 50mg of dry transaminase powder of Cat.No. 1.2.132 was added, and after stirring for 5 minutes, a dimethyl sulfoxide solution of 2-hydroxy-5-fluoroacetophenone (10 g of the starting ketone was dissolved in 100mL of dimethyl sulfoxide) was added. The vacuum is opened to the system of-0.05 MPa. The heating was turned on to 35 ℃. After 18h of reaction, the liquid phase showed <1.0% starting material remaining. Stopping stirring and carrying out suction filtration; the filter cake was rinsed with 50mL of isopropyl acetate. The filtrate was transferred to a 5L reaction flask and 1M/L dilute hydrochloric acid was added with stirring to adjust the pH of the system to 3-4. The aqueous phase was then extracted by adding 200mL of isopropyl acetate. And cooling the water phase to 10-20 ℃ after liquid separation, and adding 20% NaOH solution to adjust the pH of the system to 7-8. The aqueous phase was extracted with 500mL of isopropyl acetate. Washing the extracted organic phase with water, washing with brine, drying with anhydrous sodium sulfate, and filtering; the filtrate was concentrated to about 50mL, 50mL of petroleum ether was added, and the system was concentrated again to a volume of about 30mL, with a large amount of product being precipitated. Suction filtration and drying are carried out to obtain 8.1 g of offwhite solid with optical purity of 99.5 percent and yield of 81 percent.
The invention has various embodiments, and all technical solutions formed by adopting equivalent transformation or equivalent transformation are within the protection scope of the invention.
Claims (8)
1. A synthetic method of (R) -2- (1-aminoethyl) -4-fluorophenol is characterized in that: the method comprises the following steps of uniformly stirring an amino donor, coenzyme, a cosolvent, transaminase dry powder and a buffer solution, adding a substrate 5-fluoro-2-hydroxyacetophenone, and heating to 25-35 ℃ under a vacuum system of-0.03 MPa to-0.06 MPa for reaction; after the reaction is finished, carrying out post-treatment and purification to obtain a target product; the transaminase of the dry transaminase powder is R-configuration selective transaminase commercialized by Evoxx technologies of Germany, and is selected from the following types: cat.no. 1.2.126, cat.no. 1.2.132;
which comprises the following steps:
s1, preparing a solution of a raw material, namely preparing coenzyme into a coenzyme aqueous solution, and preparing an amino donor into an amino donor aqueous solution;
s2, adding the prepared solution in the S1 into a reaction bottle added with a buffer solution, and stirring and mixing, wherein the pH value of the buffer solution is 7-9;
s3, adding transaminase dry powder into the mixed solution of S2, uniformly stirring, adding cosolvent in which a substrate is dissolved, wherein the weight ratio of the transaminase dry powder to the substrate is 0.5-1%, keeping the vacuum degree of the system at-0.03 MPa to-0.06 MPa, heating to 25-35 ℃, and carrying out stirring reaction;
s4, stopping stirring when the content of the raw materials in the reaction liquid phase in the S3 is less than 1.0%, and finishing the reaction;
and S5, carrying out suction filtration and purification post-treatment on the solution after the reaction to obtain the target product.
2. The process for the synthesis of (R) -2- (1-aminoethyl) -4-fluorophenol according to claim 1, characterized in that: the S5 specifically includes the following steps:
s51, carrying out suction filtration on the solution after the reaction is finished, rinsing a filter cake, and transferring the filtrate;
s52, adjusting the pH of the transferred filtrate to 3-4, and adding an extraction solvent to extract a water phase;
s53, cooling the extracted water phase to 10-20 ℃, adjusting the pH to 7-8, and re-extracting the water phase;
s54, washing the organic phase extracted by the S53 with water, washing with saline water, drying and filtering in sequence;
s55, concentrating the filtrate obtained after the suction filtration of S54;
and S56, performing suction filtration again, and drying to obtain the final target product.
3. The process for the synthesis of (R) -2- (1-aminoethyl) -4-fluorophenol according to claim 1, characterized in that: the amino donor is isopropylamine, sec-butylamine or DL-alanine.
4. The process for the synthesis of (R) -2- (1-aminoethyl) -4-fluorophenol according to claim 1, characterized in that: the coenzyme in the S1 is pyridoxal phosphate.
5. The process for the synthesis of (R) -2- (1-aminoethyl) -4-fluorophenol according to claim 1, characterized in that: the concentration range of the coenzyme is 10.0 mmol/L-20.0 mmol/L.
6. The process for the synthesis of (R) -2- (1-aminoethyl) -4-fluorophenol according to claim 1, characterized in that: the cosolvent is dimethyl sulfoxide, N-dimethylformamide, methanol, ethanol, acetonitrile or isopropanol.
7. The process for the synthesis of (R) -2- (1-aminoethyl) -4-fluorophenol according to claim 1, characterized in that: the buffer solution is dipotassium phosphate buffer solution or tris buffer solution.
8. The process for the synthesis of (R) -2- (1-aminoethyl) -4-fluorophenol according to claim 2, characterized in that: the extraction solvent in S52 is ethyl acetate, isopropyl acetate, dichloromethane, toluene or methyl tert-butyl ether.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710593645.4A CN107586796B (en) | 2017-07-20 | 2017-07-20 | Synthesis method of (R) -2- (1-aminoethyl) -4-fluorophenol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710593645.4A CN107586796B (en) | 2017-07-20 | 2017-07-20 | Synthesis method of (R) -2- (1-aminoethyl) -4-fluorophenol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107586796A CN107586796A (en) | 2018-01-16 |
| CN107586796B true CN107586796B (en) | 2021-08-06 |
Family
ID=61042419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710593645.4A Active CN107586796B (en) | 2017-07-20 | 2017-07-20 | Synthesis method of (R) -2- (1-aminoethyl) -4-fluorophenol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107586796B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111876449B (en) * | 2020-07-29 | 2022-02-08 | 苏利制药科技江阴有限公司 | Preparation method of R- (-) -5- (2-aminopropyl) -2-methoxybenzenesulphonamide |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103635583A (en) * | 2011-06-15 | 2014-03-12 | 赢创德固赛有限公司 | Enzymatic amination |
| CN104131048A (en) * | 2014-08-01 | 2014-11-05 | 洛阳华荣生物技术有限公司 | Biological preparation method of R-3-aminobutanol |
| CN104328093A (en) * | 2013-11-26 | 2015-02-04 | 凯莱英医药集团（天津）股份有限公司 | R-type omega-aminotransferase and application thereof |
| WO2017033134A1 (en) * | 2015-08-26 | 2017-03-02 | Lupin Limited | Enzymatic process for the for preparation of (r)-1-(1-naphthyl) ethylamine, an intermediate of cinacalcet hydrochloride |
| CN106834372A (en) * | 2017-03-01 | 2017-06-13 | 海南大学 | A kind of transaminase living things catalysis prepare (S) or（R）The method of 2 amino-butanamides |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050009151A1 (en) * | 2003-07-10 | 2005-01-13 | Pharmacia Corporation | Methods for the stereospecific and enantiomeric enrichment of beta-amino acids |
| PT3572416T (en) * | 2014-01-24 | 2022-12-06 | Turning Point Therapeutics Inc | Diaryl macrocycles as modulators of protein kinases |
| KR101869432B1 (en) * | 2015-04-08 | 2018-06-20 | 연세대학교 산학협력단 | Omega-transaminase mutants with activity improvements toward ketones and methods for producing optically pure amines |
| CA2989327A1 (en) * | 2015-07-02 | 2017-01-05 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| DK3319969T3 (en) * | 2015-07-06 | 2024-07-08 | Turning Point Therapeutics Inc | DIARYL MACROCYCLE POLYMORPH |
| CN106191148B (en) * | 2016-07-27 | 2020-09-25 | 苏州汉酶生物技术有限公司 | Biological preparation method of (R) -3-amino-4- (2,4, 5-trifluorophenyl) tert-butyl butyrate |
-
2017
- 2017-07-20 CN CN201710593645.4A patent/CN107586796B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103635583A (en) * | 2011-06-15 | 2014-03-12 | 赢创德固赛有限公司 | Enzymatic amination |
| CN104328093A (en) * | 2013-11-26 | 2015-02-04 | 凯莱英医药集团（天津）股份有限公司 | R-type omega-aminotransferase and application thereof |
| CN104131048A (en) * | 2014-08-01 | 2014-11-05 | 洛阳华荣生物技术有限公司 | Biological preparation method of R-3-aminobutanol |
| WO2017033134A1 (en) * | 2015-08-26 | 2017-03-02 | Lupin Limited | Enzymatic process for the for preparation of (r)-1-(1-naphthyl) ethylamine, an intermediate of cinacalcet hydrochloride |
| CN106834372A (en) * | 2017-03-01 | 2017-06-13 | 海南大学 | A kind of transaminase living things catalysis prepare (S) or（R）The method of 2 amino-butanamides |
Non-Patent Citations (3)
| Title |
|---|
| Microbial synthesis of chiral amines by (R)-specific transamination with Arthrobacter sp.KNK168;A.Iwasaki et al.;《Appl Microbiol Biotechnol》;20050708;第69卷;第499-505页 * |
| Syntheses and evaluation of fluorinated conformationally restricted analogues of GABA as potential inhibitors of GABA aminotransferase;Zhiyong Wang et al.;《Bioorganic & Medicinal Chemistry》;20051128;第14卷;第2242-2252页 * |
| ω－转氨酶制备手性胺的研究进展;贾红华等;《现代化工》;20120331;第32卷(第3期);第16-22页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107586796A (en) | 2018-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2956486B1 (en) | An improved process for preparation of sugammadex sodium | |
| CN104059102B (en) | Method for preparing high-purity glufosinate-ammonium by adopting organic alkali deacidification method | |
| US10233263B1 (en) | Method for preparation of sugammadex sodium | |
| JP2009530445A5 (en) | ||
| JP2008540384A5 (en) | ||
| JP2021503306A (en) | Method for preparing amine from carbonyl compound by transaminase reaction under salt precipitation | |
| CN111574559A (en) | Post-treatment method of L-glufosinate-ammonium enzyme hydrolysate | |
| US20160340377A1 (en) | Method for purifying oxidized form of beta-nicotinamide adenine dinucleotide | |
| CN107586796B (en) | Synthesis method of (R) -2- (1-aminoethyl) -4-fluorophenol | |
| WO2010090591A1 (en) | Aminated hemicellulose molecule and method for production thereof | |
| JP7071760B2 (en) | Manufacturing method of calcobutrol | |
| CN103804179B (en) | The preparation method of chiral resolving agent and (R)-2-chloromandelic acid | |
| CN101087791B (en) | Method for producing L-biopterin | |
| CN110922417B (en) | Method for recovering cefalexin crystallization mother liquor | |
| US8637669B2 (en) | Production method for adefovir dipivoxil | |
| CN112142713A (en) | Synthesis method of imazethapyr | |
| CN100369900C (en) | A kind of preparation method of ionic liquid | |
| JP2015526507A (en) | Method for purifying fluvoxamine free base and method for producing high purity fluvoxamine maleate using the same | |
| CN108084211A (en) | A kind of recovery method of cephalexin | |
| CN108610288B (en) | Preparation method and purification method of 5-chloro-8-hydroxyquinoline | |
| CN106542979A (en) | A kind of high-selectivity synthesis method of 1,1,3 trichloroacetone | |
| CN105085513A (en) | Method for preparing (R)-3-quinuclidinol | |
| CN115304544B (en) | Synthesis method of 5-bromo-2- (methylamino) pyridine | |
| CN103772224B (en) | Preparation method of D-threonine | |
| CN102978251A (en) | Method for producing L-tert-leucine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |